Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Wuxi Biologics (Cayman) ( (HK:2269) ) has shared an announcement.
WuXi Biologics (Cayman) Inc. announced the results of its Annual General Meeting held on June 6, 2025, where all proposed resolutions were approved by shareholders. Significant changes in the board include the retirement of Dr. Weichang Zhou and the appointment of Dr. Sherry Xuejun Gu as an executive director and member of the Strategy Committee, along with Dr. Jue Chen joining the Nomination Committee. These changes are expected to influence the company’s strategic direction and governance structure.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$23.40 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a prominent player in the biopharmaceutical industry, specializing in providing end-to-end solutions for biologics discovery, development, and manufacturing. The company focuses on offering comprehensive services to global pharmaceutical and biotechnology companies, facilitating the development of innovative biologic drugs.
Average Trading Volume: 57,849,643
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.5B
Find detailed analytics on 2269 stock on TipRanks’ Stock Analysis page.